Raichur: Shilpa Medicare Limited, recently announced that its Investigational New Drug (IND), Nor-Ursodeoxycholic Acid ...

The spike in Shilpa Medicare's stock price came after the company announced the approval of its Investigational New Drug (IND ...

Gilead Sciences, Inc. has received conditional marketing authorization from the European Commission (EC) for Seladelpar for the treatment of primary biliary cholangitis (PBC) ...

Gilead Sciences, Inc. today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis (PBC) in ...

The trials identified no serious adverse effects, and patients tolerated a daily dosage of 1500 mg for 24 weeks.

GILD's strong HIV portfolio should maintain momentum for the company. The guidance for 2025 is impressive. We believe there ...

PBC is generally treated first line with ursodeoxycholic acid (UDCA), but the new entrants – including Ocaliva and elafibranor – are positioned as second-line therapies in patients who haven't ...

Non-alcoholic fatty liver disease (NAFLD) affects nearly 19 crore people in India and about a quarter of the world’s ...

The approval covers seladelpar's use in combination with ursodeoxycholic acid (UDCA ... results from future confirmatory studies. The drug offers patients the first pre-filled pen presentation ...

Gilead Sciences, Inc. GILD reported better-than-expected fourth-quarter results and provided an upbeat guidance for 2025.

If you need to fly with medication, you may have a moment of panic while packing, wondering whether you can take pills or liquid or injectable medicines on a plane or travel with prescription ...